The second half FY23 is actually a very good result given that...

The second half FY23 is actually a very good result given that they only had TMD products for only 6 month and not for a full 12 month , if the share price has reached 4.9 after the FEB update and before the release of 2HFY results then the 2HFY results should strength that . Not sure why people are panic selling . If you have bought at a discount yesterday in the morning session @3.00 you could have made 40 cents per share by the afternoon session , i wouldn't be surprised if this reach 4.9 again next week or the week after as all retail investors are selling and not the institutional where they actually do extensive research .In comparison to other ASX Listed companies that hasn't given any dividends or buy backs1HFY23 loss on 28/02 update was $99.9 m which is almost the total loss for year , 2HFY generated +ve cash flow and profit , OPEX and cost cutting and reduced interest on borrowings will all contribute to a +ve result in 1HFY24 only if they maintain the same numbers . Branded products 2HFY $48.5 so FY24 revenue $96 m . Expected PPD rev FY24 90 M AND INTERNATIONAL 74 M = Total group revenue 96+90+74 = $260 m . With the same rate revenue growth could get $m 290 so we looking at a decent earnings in 1HFY24 BETWEEN $ 10 TO $15 M . Less loss and depreciation due to divesting generic molecules .no changes to big shareholders occurred and price has re adjusted yesterday , this will go up to 5.5 before AGM . undervalued fair value 8.85